RN3161 / Rona Therapeutics - LARVOL DELTA

Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity (clinicaltrials.gov) - P1/2 | N=104 | Recruiting | Sponsor: Ikaria Bioscience Pty Ltd

Monotherapy • New P1/2 trial • Genetic Disorders • Obesity

Rona Therapeutics…announced today the successful submission of RN3161 to the Australian Human Research Ethics Committee (HREC) (PRNewswire) - "RN3161 is a proprietary GalNAc-conjugated siRNA targeting INHBE, a novel therapeutic mechanism for adults with overweight and obesity."

New trial • Obesity